

Drug Monograph

[Drug Name](#) | [Mechanism of Action and Pharmacokinetics](#) | [Indications and Status](#) | [Adverse Effects](#) | [Dosing](#) | [Administration Guidelines](#) | [Special Precautions](#) | [Interactions](#) | [Recommended Clinical Monitoring](#) | [Supplementary Public Funding](#) | [References](#) | [Disclaimer](#)

A - Drug Name

temsirolimus

SYNONYM(S): cell cycle inhibitor 779 (CCI-779); rapamycin analog CCI-779

COMMON TRADE NAME(S): Torisel®

[back to top](#)

B - Mechanism of Action and Pharmacokinetics

Temsirolimus, an ester analog of sirolimus, is an inhibitor of mammalian target of rapamycin (mTOR). mTOR, a protein kinase, is involved in a variety of cell signalling events in the P13 kinase/AKT pathway that control cell division, and result in G1 growth arrest in treated tumour cells. It has anti-angiogenic effects by regulating hypoxia-inducible factors (HIF) and vascular endothelial growth factor (VEGF).

Absorption Following a single 25 mg IV dose in patients with cancer, sirolimus AUC was 2.7-fold that of temsirolimus AUC, due principally to the longer half-life of sirolimus. Following varying IV temsirolimus doses, the AUC (sum of temsirolimus and sirolimus) is dose-related, but non-proportional. Significantly higher exposure was observed in Japanese patients.

Distribution

Well distributed to tissues	
Cross blood brain barrier?	yes
PPB	Temsirolimus (87%); Sirolimus (92%)

Metabolism Temsirolimus is metabolized primarily by CYP3A4 in the liver and is an inhibitor of CYP3A4/5 and CYP2D6. It is also a substrate and potential

	inhibitor of P-glycoprotein. Additional metabolic pathways include hydroxylation, reduction and demethylation.	
	Active metabolites	yes (sirolimus)
	Inactive metabolites	yes
Elimination	Feces	78%
	Urine	4.6%
	Half-life	Mean half-life: 17.3 h (temsirolimus); 54.6 h (sirolimus)

[back to top](#)

C - Indications and Status

Health Canada Approvals:

- Renal cell carcinoma

Refer to the product monograph for a full list and details of approved indications.

[back to top](#)

D - Adverse Effects

Emetogenic Potential: Minimal

Extravasation Potential: None

The following table contains side effects from the pivotal phase III study in metastatic renal cell carcinoma.

ORGAN SITE	SIDE EFFECT* (%)	ONSET**
Cardiovascular	Hypertension (7%)	E
	Pericardial effusion (1%)	E
	QT interval prolonged (rare)	I E

	Venous thromboembolism (2%)	E
Dermatological	Hand-foot syndrome (rare)	E
	Nail disorder (14%)	E
	Rash (47%) (may be severe)	I E
Gastrointestinal	Abdominal pain (21%)	E
	Anorexia, weight loss (32%)	E
	Constipation (21%)	E
	Diarrhea (27%)	E
	GI perforation (1%)	E
	Mucositis (41%)	E
	Nausea, vomiting (37%)	E
General	Delayed wound healing (1%)	E
	Edema (42%) (may be severe)	E
	Fatigue (51%)	E
Hematological	Hemorrhage (25%) (3% severe)	E
	Myelosuppression (mainly anemia; up to 20% severe)	E
Hepatobiliary	↑ LFTs (68%) (3% severe)	E
Hypersensitivity	Hypersensitivity (9%)	I
Infection	Infection (31%) (including opportunistic)	E
Metabolic / Endocrine	Abnormal electrolyte(s) (21-50%; K, Ca, PO ₄)	E
	Hyperglycemia (89%) (16% grade 3-4)	E
	Hyperlipidemia (87%) (2% grade 3-4)	E
Musculoskeletal	Musculoskeletal pain (20%)	E
	↑CPK (rare)	E
	Rhabdomyolysis (rare)	E
Neoplastic	Secondary malignancy (rare)	D L
Nervous System	Dysgeusia (20%)	E
	Insomnia (12%)	E
	Seizure (rare)	E
Ophthalmic	Conjunctivitis (7%)	E
Renal	Creatinine increased (57%) (3% severe)	E
Respiratory	Cough, dyspnea (30%)	E
	Interstitial lung disease (pneumonitis; 2%)	E L
	Pleural effusion (5%)	E

* "*Incidence*" may refer to an absolute value or the higher value from a reported range.
 "*Rare*" may refer to events with < 1% incidence, reported in post-marketing, phase 1 studies, isolated data or anecdotal reports.

** I = *immediate* (onset in hours to days) E = *early* (days to weeks)
 D = *delayed* (weeks to months) L = *late* (months to years)

The most common adverse reactions associated with temsirolimus were **rash, fatigue, mucositis, nausea, edema, and anorexia, hyperlipidemia, hyperglycemia.**

Hypersensitivity reactions (anaphylactic reactions, hypotension, dyspnea, flushing and/or chest pain) have been associated with temsirolimus. These can occur early in the first infusion, as well as in subsequent infusions. Patients should receive prophylactic H₁ antihistamine, i.e. diphenhydramine 25 to 50mg, 30 minutes prior to the administration of temsirolimus. **Angioneurotic edema** has been reported especially in combination with ACEI / calcium channel blockers, and may occur after temsirolimus treatment has been discontinued.

Interstitial lung disease (ILD, pneumonitis) has been associated with temsirolimus and may be life-threatening/fatal. Symptoms include dry cough, fever, eosinophilia, chest pain, and dyspnea on exertion. The risk of ILD is increased with temsirolimus doses greater than 25 mg. Monitor patients for symptoms or radiographic changes of ILD. Advise patients to promptly report any new or worsening respiratory symptoms. (See Section E - Dosing)

Hyperglycemia associated with temsirolimus may require patients with diabetes mellitus (DM) to adjust dosages of their antidiabetic medications, while patients without a history of DM may need the initiation of insulin or oral hypoglycemic agent therapy.

Hyperlipidemia is common and patients who require statins should be carefully monitored, as there may be an increased risk of rhabdomyolysis. (See Interactions section)

Temsirolimus may be **immunosuppressive**. Patients should be carefully observed for the occurrence of infections, including opportunistic infections. Consider prophylaxis of pneumocystis jiroveci pneumonia (PJP).

Pleural and cardiac effusions and other cardiac events have been reported in patients taking ACE inhibitors (see Drug Interactions).

[back to top](#)

E - Dosing

Refer to protocol by which patient is being treated.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the [hepatitis B virus screening and management](#) guideline.

Do not administer if bilirubin > 1.5 x ULN.

Pre-medications (prophylaxis for infusion reaction):

- Diphenhydramine 25-50 mg IV (or equivalent) should be given 30 minutes before the start of the infusion.

Adults:

Intravenous: 25mg once weekly

Dosage with Toxicity:

Toxicity and Grade	Action	Dose
Pneumonitis (grade 1 or 2)	Hold until \leq grade 1; may continue if asymptomatic. Consider steroids.	Consider dose reduction (by 5mg/week)*
Pneumonitis (grade 3 or 4)	Discontinue, consider steroids	Discontinue permanently
Intolerable grade 2 non-hematological	May continue <u>AND</u>	Reduce by 5mg/week*
Grade 3 or 4 non-hematological	Hold until recovered to \leq grade 2 <u>AND</u>	Reduce by 5mg/week*
Platelet < $75 \times 10^9/L$ and/or ANC < $1 \times 10^9/L$	Hold until recovery to $\geq 75 \times 10^9/L$ and $\geq 1 \times 10^9/L$ <u>AND</u>	Reduce by 5mg/week*

*Minimum dose is 15mg/week

Management of Infusion-related reactions:

Also refer to the CCO guideline for detailed description of [Management of Cancer Medication-Related Infusion Reactions](#).

Grade	Action
1 or 2	<ul style="list-style-type: none"> • Stop the infusion and observe the patient for at least 30-60 minutes. • If deemed appropriate by the physician, temsirolimus may be resumed. • Administer a H₁-receptor antagonist if one was not previously administered and/or a H₂-receptor antagonist, such as famotidine 20mg IV or ranitidine 50mg IV, approximately 30 minutes before restarting the infusion. • Restart at a slower rate of up to 60 minutes.
3 or 4	<ul style="list-style-type: none"> • Stop the infusion. Treat symptoms with antihistamines, antipyretics, beta-agonists and/or corticosteroids as appropriate. Consider discontinuing temsirolimus treatment.

Dosage with Hepatic Impairment:

Hepatic metabolism is significant.

	AST	Bilirubin	Action
Mild	> ULN	≤ ULN	Caution. Dose at 15mg
		>1 - 1.5 x ULN	Caution. Dose at 15mg
Moderate to severe		>1.5 x ULN	Do not treat.

Dosage with Renal Impairment:

Use with caution. No formal studies have been performed in renally impaired patients. Dose adjustment may not be required since <5% of the dose is excreted in the urine. Temsirolimus use in hemodialysis was described in a case series.

Dosage in the elderly:

No dose adjustment is required. Elderly patients may be more likely to experience edema, diarrhea and pneumonia. Overall survival was shorter in patients 65 years or older.

Children:

Effectiveness in children was not established.

[back to top](#)

F - Administration Guidelines

- Inject supplied diluent (contains polysorbate 80 and PEG 400) into the drug vial and then dilute further in 250mL Normal Saline; infuse over 30 -60 minutes. Avoid excessive shaking as this may cause foaming.
- To decrease di-(2-ethylhexyl) phthalate (DEHP) leaching or avoid excessive drug loss, materials used in administration must be composed of glass, polyolefin or polyethylene. Use a non-PVC non-DEHP tubing, including an in-line polyethersulfone filter \leq 5 microns. A polyethersulfone end-filter (0.2 to 5 microns) may be added if the administration set does not have an in-line filter component. The use of both an in-line and end-filter is not recommended.
- The drug concentrate-diluent mixture is stable for up to 24 hours at room temperature and protected from light. The final diluted drug solution should be completely administered within 6 hours from the time that the concentrate-diluent mixture is added to the Normal Saline bag.
- Keep unopened drug and diluent vials refrigerated (2-8°C); do not freeze.
- Protect the drug and diluted solutions from light. Do not use if drug is discoloured or if particulates are present.

[back to top](#)

G - Special Precautions

Contraindications:

- patients with known hypersensitivity to this sirolimus, temsirolimus, or any ingredients in the formulation
- patients with elevated bilirubin ($> 1.5 \times \text{ULN}$)

Other Warnings/Precautions:

- patients with pre-existing or at risk of prolonged QTc
- patients with brain metastases (increased risk of bleeding)
- patients who have known hypersensitivity to an antihistamine or cannot receive an antihistamine for other medical reasons
- patients on anticoagulants or who have had recent surgery
- avoid use of live vaccines

Other Drug Properties:

- Carcinogenicity: Probable

Pregnancy and Lactation:

- Genotoxicity: No
- Embryotoxicity: Yes
- Fetotoxicity: Yes
Temsiroliimus is not recommended for use in pregnancy. Adequate contraception should be used by patients and their partners during treatment, and for at least **3 months** after the last dose.
- Excretion into breast milk: Unknown
Breastfeeding is not recommended.
- Fertility effects: Probable

[back to top](#)

H - Interactions

CYP3A4 is the major CYP isozyme responsible for the metabolism of temsirolimus and the active metabolite, sirolimus.

AGENT	EFFECT	MECHANISM	MANAGEMENT
CYP3A4 inhibitors (e.g. ketoconazole, nefazodone, clarithromycin, itraconazole, ritonavir, verapamil, grapefruit juice, aprepitant, erythromycin, fluconazole)	↑ sirolimus concentrations (↑ AUC by 3.1-fold with ketoconazole)	↓ metabolism of CYP3A4 substrates	Avoid concomitant usage with strong CYP3A4 inhibitors
CYP3A4/5 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or St. John's Wort, nevirapine)	↓ sirolimus concentrations (↓ Cmax by 65% and ↓ AUC by 56% with rifampin)	↑ metabolism of CYP3A4 substrates	Avoid concomitant usage with strong CYP3A4 inducers
CYP3A4/5 substrates (e.g. HMG CoA reductase inhibitors, macrolide antibiotics, benzodiazepine, pimozone, quinidine, ergot alkaloids)	↑ substrate's concentrations (theoretical)	Temsirolimus inhibits CYP3A4/5 in vitro	Caution. Monitor for signs and symptoms of substrate toxicity. (e.g. rhabdomyolysis with statins).
CYP2D6 substrates (e.g. desipramine, amitriptyline, paroxetine, fluoxetine, haloperidol,	↑ substrate's concentrations	Temsirolimus inhibits CYP2D6 in vitro	Caution. Monitor for signs and symptoms of substrate toxicity.

risperidone)			
Gemcitabine, 5FU, Sunitinib	Severe GI, rash, other toxicity	Additive	Avoid or use with extreme caution
Anticoagulants	↑ risk of intracerebral bleeding in patients with CNS tumours	Additive	Extreme Caution
ACE Inhibitors (e.g., enalapril, lisinopril, ramipril) or calcium channel blockers (e.g., amlodipine)	↑ risk of angioneurotic edema (may be delayed)	Unknown	Caution
Cannabidiol	↑ temsirolimus toxicity	↑ levels of other mTOR inhibitors were observed	Caution; monitor for toxicity
Pgp substrates	↓ transport of digoxin in vitro	inhibition of Pgp	Caution
Drugs that may prolong QT (i.e. Amiodarone, procainamide, sotalol, venlafaxine, amitriptyline, sunitinib, methadone, chloroquine, clarithromycin, haloperidol, fluconazole, moxifloxacin, domperidone, ondansetron, etc)	↑ risk of Torsades de pointes	Additive	Avoid if possible; caution and monitor if used together

[back to top](#)

I - Recommended Clinical Monitoring

Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.

Refer to the [hepatitis B virus screening and management](#) guideline for monitoring during and after treatment.

Recommended Clinical Monitoring

Monitor Type	Monitor Frequency
CBC	Baseline and weekly
Fasting glucose	Baseline and weekly
Liver function tests	Baseline and every 2 weeks
Renal function tests & electrolytes	Baseline and every 2 weeks
Lipids	Baseline and monthly
Radiologic screening for ILD	Baseline and periodic
Routine assessment for signs and symptoms of fatigue, hyperglycemia, bleeding, pneumonitis, fluid retention, skin toxicity, infections, mucositis, delayed wound healing, infusion reactions, rhabdomyolysis (especially with statins).	At each visit

Grade toxicity using the current [NCI-CTCAE \(Common Terminology Criteria for Adverse Events\) version](#)

[back to top](#)

J - Supplementary Public Funding

New Drug Funding Program ([NDFP Website](#))

- Temsirolimus - Metastatic Renal Cell Carcinoma

[back to top](#)

K - References

Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. *Annals of Oncology* 2008; 19: 1387–92.

Duran I, Siu L, Oza A, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. *Eur J Cancer*. 2006;42(12):1875-80.

Kuhn JG, Chang SM, Wen PY et al. Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma. *Clin Cancer Res* 2007; 13: 7401-7406.

Lunardi G, Vanzo MO, Arminotti A, et al. Temsirolimus in Patients With Renal Cancer on Hemodialysis. *JCO* 2008; 26(34): 5652-4.

Product Monograph: Torisel® (temsirolimus). Pfizer Canada, July 2022.

Product Monograph: Torisel® (temsirolimus). Pfizer (US), May 2012.

Simpson D, Curran MP. Temsirolimus in advanced renal cell carcinoma. *Drugs* 2008; 68(5): 631-38.

June 2024 Modified Interactions and Monitoring sections

[back to top](#)

L - Disclaimer

Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare

providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary's content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

[back to top](#)